Zachary Vest, MD
Ophthalmology · Sheridan, CONPI 1477715829
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AbbVie at 54.5% of the total. 2025 is the largest year on record at $12,114, more than ten times the $849 reported in 2019. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 305 payments — averaging $126.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$21K
- Glaukos Corporation$6K
- Bausch & Lomb Americas Inc.$6K
- NEW World Medical,inc.$2K
- Alcon$1K
- Sight Sciences, Inc.$653
- plus $1K from 17 others
Across 31 payments — averaging $1446.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$37K
- Alcon Research LLC$7K
What the payments were for
- Consulting fees$10,12526%
- Speaking & faculty fees$16,88244%
- Food & beverage$11,65830%
- Education$180%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $21,107 |
| Glaukos Corporation | 47 | $6,270 |
| Bausch & Lomb Americas Inc. | 8 | $6,223 |
| NEW World Medical,inc. | 24 | $1,706 |
| Alcon | 71 | $1,430 |
| Sight Sciences, Inc. | 15 | $653 |
| Carl Zeiss Meditec USA, Inc. | 7 | $270 |
| Rxsight Inc | 6 | $261 |
| Ivantis, Inc | 1 | $149 |
| Aerie Pharmaceuticals, Inc. | 4 | $91 |
| Kala Pharmaceuticals, Inc. | 4 | $75 |
| Ocular Therapeutix, Inc. | 4 | $69 |
| Harrow Eye, LLC | 4 | $69 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $65 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Rayner Intraocular Lenses Limited | 2 | $49 |
| Tarsus Pharmaceuticals, Inc. | 1 | $37 |
| Staar Surgical Company | 1 | $35 |
| Oyster Point Pharma, Inc. | 1 | $29 |
| Nova Eye, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$18,999
- iDose$1,835
- iDose TR$1,650
- Kahook Dual Blade$620
- Ahmed Glaucoma Valve$620
- iDoseTR$483
- OMNI(R) SURGICAL SYSTEM (US)$429
- Clearpath$418
- Streamline$418
- iStent Infinite$363
- Via360$300
- DURYSTA$226
- Streamline Surgical System$202
- Hydrus$149
- SION SURGICAL INSTRUMENT$144
- Hydrus Microstent$143
- XEN$133
- VYZULTA$124
- Clareon$117
- RXSIGHT CONTACT LENS$113
How this compares
$38,728 in reported general payments places this provider in the 90th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 163 | $82,377 |
| RocklatanNetarsudil Mesylat/Latanoprost | 78 | $40,444 |
| RhopressaNetarsudil Mesylate | 78 | $34,984 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 81 | $22,556 |
| RestasisCyclosporine | 19 | $19,339 |
| Prednisolone Acetate | 335 | $16,512 |
| Ketorolac Tromethamine | 563 | $14,820 |
| VyzultaLatanoprostene Bunod | 32 | $13,525 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $12,227 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 63 | $12,068 |
| Brimonidine Tartrate | 290 | $10,487 |
| Latanoprost | 902 | $10,104 |
| Loteprednol Etabonate | 57 | $8,735 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 556 | $8,359 |
| Travoprost | 58 | $8,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $21,107 | $121,056238 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $91 | $75,429156 claims |
| AlconSimbrinza | $1,430 | $22,55681 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Lotemax Sm | $65 | $18,11084 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $6,223 | $13,52532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Sheridan
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
- Steven DeweyColorado Springs$246K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.